SCYX SCYNEXIS, Inc.
Mergers ·
Under an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license.
SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance.
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with its lead program in difficult-to-treat and drug-resistant fungal infections. It is developing its proprietary fungerp platform of triterpenoid antifungal agents, which are structurally distinct glucan synthase inhibitors. Ibrexafungerp, the first representative of the class, was approved by the FDA as BREXAFEMME for vulvovaginal candidiasis and for reducing the incidence of recurrent vulvovaginal candidiasis, in 2021 and 2022 respectively. Ibrexafungerp was licensed to GSK in May 2023. The second-generation compound SCY-247 is being evaluated in clinical trials, and the company completed the single and multiple ascending dose portions of an ongoing Phase 1 study of oral SCY-247 in 88 healthy subjects. The FDA has granted SCY-247 Qualified Infectious Disease Product status and Fast Track designations for the oral formulation. Other compounds from the platform are in earlier stages of development.
| Product or program | What it is | Stage |
|---|---|---|
| BREXAFEMME (ibrexafungerp) | Oral antifungal for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, licensed to GSK | approved by the FDA |
| SCY-247 | Second-generation oral fungerp antifungal for drug-resistant fungal infections | in clinical trials; Phase 1 study ongoing |
| Other fungerp platform compounds | Compounds from the proprietary fungerp platform targeting unmet needs | earlier stages of development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $22.3 million | $26.4 million |
| Net income (loss) | -$8.6 million | -$21.3 million |
| Cash from operations | -$5.3 million | -$24.0 million |
| Cash and equivalents | $21.3 million | $16.1 million |
| Short-term investments | $18.8 million | $43.2 million |
Our latest story on this, dated Nov 6, 2024: "SCYNEXIS sets up at-the-market program for up to $50,000,000 of stock with Cantor". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 26, 2025: "SCYNEXIS gets Nasdaq minimum bid price notice, has until December 17, 2025 to comply". The story links the filing or release it is based on. Read the story.
SCYNEXIS, Inc. trades under the ticker SCYX on NASDAQ.
SCYNEXIS, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0L49.
The SEC Central Index Key (CIK) for SCYNEXIS, Inc. is 1178253. Its filings are on SEC EDGAR.
9,949,609 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-10.
Our directory records SCYNEXIS, Inc. under United States.
Our directory classifies SCYNEXIS, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for SCYNEXIS, Inc. is US8112923094.
aibio.space lists SCYNEXIS, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with its lead program in difficult-to-treat and drug-resistant fungal infections. It is developing its proprietary fungerp platform of triterpenoid antifungal agents, which are structurally distinct glucan synthase inhibitors.
BREXAFEMME (ibrexafungerp): Oral antifungal for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, licensed to GSK Stage: approved by the FDA.
SCY-247: Second-generation oral fungerp antifungal for drug-resistant fungal infections Stage: in clinical trials; Phase 1 study ongoing.
SCYNEXIS, Inc. reported a net loss of $8.6 million for the fiscal year ended Dec 31, 2025, and used $5.3 million of cash in operations, per its annual report to the SEC.
$22.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio